<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3229">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01970501</url>
  </required_header>
  <id_info>
    <org_study_id>BUC-CLIN-303</org_study_id>
    <nct_id>NCT01970501</nct_id>
  </id_info>
  <brief_title>Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure</brief_title>
  <acronym>GENETIC-AF</acronym>
  <official_title>GENETIC-AF - A Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients With Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ARCA Biopharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ARCA Biopharma, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to compare the effects of bucindolol hydrochloride (bucindolol) to
      metoprolol succinate (Toprol-XL) on the recurrence of symptomatic atrial fibrillation/atrial
      flutter in patients with heart failure who have a specific genotype for the beta-1
      adrenergic receptor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of the GENETIC-AF trial is to demonstrate the superiority of pharmacogenetically
      targeted bucindolol compared to Toprol-XL for the prevention of symptomatic atrial
      fibrillation or atrial flutter in a genotype-defined population with heart failure and/or
      reduced left ventricular ejection fraction that has persistent symptomatic AF requiring
      electrical conversion to sinus rhythm.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Time to first event of symptomatic atrial fibrillation/atrial flutter (AF/AFL) or all cause mortality (ACM) during the 24-week Follow-up Period after conversion to stable sinus rhythm (SR)</measure>
    <time_frame>end of treatment week 24</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first event of AF/AFL (i.e., symptomatic or asymptomatic) or ACM during the 24-week Follow-up Period</measure>
    <time_frame>end of treatment week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients during the 24-week Follow-up Period with ventricular tachycardia (VT), ventricular fibrillation (VF), or symptomatic supraventricular tachycardia (SVT)</measure>
    <time_frame>end of treatment week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of hospitalization (all-cause) days per patient during the Total Study Period</measure>
    <time_frame>4 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first event of ACM or heart failure (HF) hospitalization (as assessed by the Investigator) during the Total Study Period</measure>
    <time_frame>4 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who have AF on ECG at the end of the study who demonstrate ventricular response rate (VRR) control</measure>
    <time_frame>4 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of ACM during the Total Study Period</measure>
    <time_frame>4 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of ACM, cardiovascular-related hospitalization (as assessed by the Investigator), or withdrawal of study drug due to an adverse event (AE) during the Drug Titration Period</measure>
    <time_frame>end of treatment week 8</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Incidence during the Total Study Period of third degree heart block, second degree heart block requiring pacemaker implantation, or symptomatic second degree heart block as determined by the Clinical Events Committee</measure>
    <time_frame>4 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Incidence and severity of treatment-emergent Adverse Events/Serious Adverse Events over time</measure>
    <time_frame>4 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline (randomization) over time on clinical laboratory tests, vital signs and weight</measure>
    <time_frame>4 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of patients attaining target study drug dose for the subpopulations receiving and not receiving previous beta blocker therapy at randomization</measure>
    <time_frame>end of treatment week 8</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">620</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Atrial Flutter</condition>
  <arm_group>
    <arm_group_label>bucindolol hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bucindolol hydrochloride (bucindolol)
Capsules are available in the following dosage strengths to be taken twice daily (with or without food): 6.25mg, 12.5mg, 25mg, 50mg, and 100mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>metoprolol succinate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>metoprolol succinate (Toprol-XL)
Capsules are available in the following dosage strengths to be taken twice daily (with or without food): 25mg, 50mg, 100mg, 200mg and/or matching placebo to maintain blinded dosing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bucindolol hydrochloride</intervention_name>
    <arm_group_label>bucindolol hydrochloride</arm_group_label>
    <other_name>bucindolol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metoprolol succinate</intervention_name>
    <arm_group_label>metoprolol succinate</arm_group_label>
    <other_name>Toprol-XL</other_name>
    <other_name>metoprolol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Must weigh ≥ 40 kg

          -  New York Heart Association (NYHA) Class I-III

          -  Recent onset of symptomatic persistent AF, determined by the Investigator to require
             electrical cardioversion (ECV)

          -  Possess the β1389Arg/Arg genotype

          -  Left Ventricular Ejection Fraction (LVEF) &lt; 0.50 assessed ≤ 12 months prior to Visit
             1.

          -  Left ventricular internal diameter in diastole (LVIDD) ≥ 2.7 cm/m2 assessed ≤ 12
             months prior to Visit 1

          -  Clinical euvolemia at the time of randomization

          -  Receiving appropriate anticoagulation therapy prior to randomization

          -  Must either have a Medtronic implanted device that can measure atrial fibrillation
             burden (AFB), or agree to have one inserted as clinically indicated

        Key Exclusion Criteria:

          -  Use of any of the following ≤ 7 days of Visit 2: Amiodarone, disopyramide,
             dofetilide, dronedarone, encainide, flecainide, propafenone, sotalol, calcium channel
             blockers, theophylline, daily NSAIDS (e.g. ibuprofen, celecoxib), thiazolidinediones,
             or frequent use of nitroglycerin (i.e., &gt; 6 sublingual tablets/week)

          -  Chronic use (&gt; 2 days/week) of an inhaled β2-selective adrenergic agonist ≤ 7 days of
             Visit 2

          -  More than two previous ECV ≤ 12 months of Visit 1 or if the most recent ECV failed to
             produce SR

          -  Evidence of paroxysmal AF during the Screening Period

          -  History of a successful atrioventricular (AV) node ablation

          -  History of an AF ablation within 3 months of Visit 1

          -  Myocardial infarction, unstable angina, acute coronary syndrome, cardiac surgery
             (including percutaneous transluminal coronary angioplasty or stent placement), or
             evidence of new ischemic changes as assessed by ECG within 90 days of Visit 1 or at
             any time during the Screening Period

          -  Evidence of an appropriate firing of an implanted cardioverter-defibrillator (ICD)
             device for ventricular tachycardia (VT) or ventricular fibrillation (VF) ≤ 90 days of
             Visit 2
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Piccini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chris Dufton, PhD</last_name>
    <role>Study Director</role>
    <affiliation>ARCA Biopharma, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Meriwether</last_name>
    <phone>720-940-2132</phone>
    <email>jennifer.meriwether@arcabiopharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>ARCA Clinical Research Site #194</name>
      <address>
        <city>Gurnee</city>
        <state>Illinois</state>
        <zip>60031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ARCA Clinical Research Site #162</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ARCA Clinical Research Site #152</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ARCA Clinical Research Site #161</name>
      <address>
        <city>Elmer</city>
        <state>New Jersey</state>
        <zip>08318</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ARCA Clinical Research Site #151</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ARCA Clinical Research Site #123</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ARCA Clinical Research Site #114</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ARCA Clinical Research Site #198</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Liggett SB, Mialet-Perez J, Thaneemit-Chen S, Weber SA, Greene SM, Hodne D, Nelson B, Morrison J, Domanski MJ, Wagoner LE, Abraham WT, Anderson JL, Carlquist JF, Krause-Steinrauf HJ, Lazzeroni LC, Port JD, Lavori PW, Bristow MR. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11288-93. Epub 2006 Jul 14.</citation>
    <PMID>16844790</PMID>
  </reference>
  <reference>
    <citation>O'Connor CM, Fiuzat M, Carson PE, Anand IS, Plehn JF, Gottlieb SS, Silver MA, Lindenfeld J, Miller AB, White M, Walsh R, Nelson P, Medway A, Davis G, Robertson AD, Port JD, Carr J, Murphy GA, Lazzeroni LC, Abraham WT, Liggett SB, Bristow MR. Combinatorial pharmacogenetic interactions of bucindolol and β1, α2C adrenergic receptor polymorphisms. PLoS One. 2012;7(10):e44324. doi: 10.1371/journal.pone.0044324. Epub 2012 Oct 10.</citation>
    <PMID>23071495</PMID>
  </reference>
  <reference>
    <citation>Aleong RG, Sauer WH, Davis G, Murphy GA, Port JD, Anand IS, Fiuzat M, O'Connor CM, Abraham WT, Liggett SB, Bristow MR. Prevention of Atrial Fibrillation by Bucindolol Is Dependent on the Beta(1)389 Arg/Gly Adrenergic Receptor Polymorphism. JACC Heart Fail. 2013 Aug 1;1(4):338-344.</citation>
    <PMID>24159564</PMID>
  </reference>
  <reference>
    <citation>Kao DP, Davis G, Aleong R, O'Connor CM, Fiuzat M, Carson PE, Anand IS, Plehn JF, Gottlieb SS, Silver MA, Lindenfeld J, Miller AB, White M, Murphy GA, Sauer W, Bristow MR. Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation. Eur J Heart Fail. 2013 Mar;15(3):324-33. doi: 10.1093/eurjhf/hfs181. Epub 2012 Dec 7.</citation>
    <PMID>23223178</PMID>
  </reference>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 17, 2014</lastchanged_date>
  <firstreceived_date>October 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>atrial flutter</keyword>
  <keyword>heart failure</keyword>
  <keyword>reduced left ventricle ejection fraction</keyword>
  <keyword>electrical cardioversion</keyword>
  <keyword>GENETIC-AF</keyword>
  <keyword>Medtronic</keyword>
  <keyword>bucindolol</keyword>
  <keyword>pharmacogenetic</keyword>
  <keyword>ARCA</keyword>
  <keyword>Toprol</keyword>
  <keyword>Toprol-XL</keyword>
  <keyword>Metoprolol</keyword>
  <keyword>Metoprolol succinate</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Atrial Flutter</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Metoprolol succinate</mesh_term>
    <mesh_term>Bucindolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
